Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
Visa övriga samt affilieringar
2010 (Engelska)Ingår i: American Journal of Hypertension, ISSN 0895-7061, E-ISSN 1941-7225, Vol. 23, nr 7, s. 786-793Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background 

Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes. However, whether concomitant hydrochlorothiazide (HCTZ) therapy in >70% of LIFE patients was associated with greater regression of LVH independent of BP changes and whether this effect differed between treatment arms has not been examined.

Methods 

Changes in Cornell product and Sokolow–Lyon voltage LVH were assessed in 9,193 hypertensive patients randomly assigned to treatment with losartan or atenolol, with additional HCTZ therapy added as necessary to achieve target BP goal per study protocol.

Results 

After controlling for baseline and change in systolic and diastolic pressure, age, sex, race, prior antihypertensive treatment, baseline and year-4 body mass index and baseline LVH by either Cornell product or Sokolow–Lyon voltage, at year-4 follow-up HCTZ therapy was associated with greater regression of Cornell product LVH (−244 ± 788 vs. −172 ± 771 mm·msec, P < 0.05) and Sokolow–Lyon voltage (−4.2 ± 6.7 vs. −3.0 ± 7.0 mm, P < 0.001) and this effect was significantly greater in patients on losartan (−341 ± 743 vs. −189 ± 775 mm·msec and −5.2 ± 6.6 vs. −3.3 ± 6.6 mm) than in patients on atenolol (−142 ± 822 vs. −158 ± 765 mm·msec and −3.1 ± 6.6 vs. −2.7 ± 7.4 mm; both P < 0.001 for interaction of HCTZ with losartan vs. atenolol therapy).

Conclusions 

HCTZ use was associated with greater regression of ECG LVH and this effect was greater in patients on losartan- than atenolol-based therapy, independent of baseline severity of ECG LVH and hypertension and changes in BP.

Ort, förlag, år, upplaga, sidor
2010. Vol. 23, nr 7, s. 786-793
Nyckelord [en]
blood pressure; drugs; electrocardiography; hypertension
Nationell ämneskategori
Kardiologi
Identifikatorer
URN: urn:nbn:se:umu:diva-41555DOI: 10.1038/ajh.2010.65ISI: 000279119700017Scopus ID: 2-s2.0-77953810908OAI: oai:DiVA.org:umu-41555DiVA, id: diva2:406834
Tillgänglig från: 2011-03-28 Skapad: 2011-03-28 Senast uppdaterad: 2023-03-24Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextScopus

Person

Lindholm, Lars H

Sök vidare i DiVA

Av författaren/redaktören
Lindholm, Lars H
Av organisationen
Allmänmedicin
I samma tidskrift
American Journal of Hypertension
Kardiologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 270 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf